SEC EDGARJUN 242 min read$COR

Tyler Lauren M purchased $149K of COR

Tyler Lauren M purchased 550 shares of Cencora, Inc. (COR) at $270.23 ($0.15M total) on 2026-06-22.

Original reporting

SEC EDGAR · Tyler Lauren M

Published Jun 24, 2026, 8:04 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 24, 2026, 8:09 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$COR

Bullish

low confidence

Mentioned

$COR

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CORBullishLow

Why it matters

The newest fact is the director’s open-market purchase details (550 shares at $270.23; ~$148.6K total). This can marginally support sentiment but does not change earnings, guidance, or risk materially.

Market read

Useful for tracking insider activity, but the transaction size and lack of fundamental updates make it low-conviction for trading decisions.

What to watch

No 10b5-1 plan is noted, but the article provides no context on prior holdings, motivation, or whether other insiders made similar moves.

Relevance 5/10Novelty 5/10Timing: SEC Form 4 filed 2026-06-24 (transaction dated 2026-06-22).

Background

The article is an SEC Form 4 insider transaction disclosure for Cencora, Inc. (COR).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CORBullishLow confidence

Context

Cencora (COR) disclosed via SEC Form 4 that director Tyler Lauren M bought 550 shares at $270.23 on 2026-06-22 for ~$148.6K.

Expected impact

Likely limited near-term price impact; any effect is small and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 insider transaction with no 10b5-1 plan and no accompanying company-specific operational or financial update.

Market effects

Sector

Minimal; insider buying at a single healthcare distributor does not materially change sector fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider purchases can be discretionary, tax/portfolio-driven, or small relative to typical trading volumes, so they may not reflect a new view on fundamentals.

Key entities

public_company
Cencora, Inc.
Issuer of the Form 4 insider transaction; director Tyler Lauren M purchased shares.
insider
Tyler Lauren M
Director who reported an open-market purchase of 550 shares on 2026-06-22.

Read at source ← All news

SEP 10

$CORHighAI 8/10

Is Cencora Stock Underperforming the Dow?

Cencora (COR), a $61.6B pharmaceutical distributor, is down 14% from its 52-week high but up 18.5% over 3 months, outperforming the Dow. Its Q3 revenue missed estimates, but adjusted EPS beat forecasts. Analysts rate it a 'Strong Buy' with a $366.50 target, implying 12.9% upside. Peer Cardinal Health (CAH) gained 60% over the past year.

yahoo.com2 min

SEP 8

$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

yahoo.com3 min

SEP 6

$CORHighAI 8/10

Why Cencora (COR) Is Getting Attention Today

Cencora (COR) reported Q3 2026 adjusted EPS of $4.48, beating estimates, and raised full-year guidance. Shares fell 1.86% to $330.95 but gained 20.75% over 90 days. The company's long-term returns are strong, with a 1-year return of 14.01% and a 5-year return of 183.23%. Analysts suggest fair value at $372.58, citing digital investments and healthcare trends.

simplywall.st2 min

AUG 23

$MCKMedAI 8/10

and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

McKesson (MCK) and Cencora (COR) are positioned to benefit from certain drug price inflation due to contractual provisions. McKesson reported $403.4B revenue and $39.11 EPS for fiscal 2026, with Q1 2027 revenue at $105.4B and EPS at $9.93. Cencora generated $321.3B revenue in fiscal 2025, with Q2 revenue at $78.4B and EPS at $4.75. Both companies have raised EPS forecasts.

aol.com3 min

AUG 21

$MCKHighAI 9/10

With Price-Increase Clauses, These Two Drug Distributors Can Withstand ‘Trumpflation’

McKesson (MCK) and Cencora (COR) benefit from drug price increases due to inflation-based compensation clauses. McKesson reported $403.4B revenue in 2026, up 12%, and raised EPS guidance. Cencora posted $321.3B revenue in 2025, up 3.8%, and increased EPS guidance. Both companies' contracts allow gains from manufacturer price hikes, but risks include regulation and cost pressures.

nai500.com3 min

AUG 20

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

finance.yahoo.com3 min